RxSight (RXST). The company produces lenses that improve the vision of patients after cataract surgery, and also sells related ophthalmic devices.
The leading product of RxSight is intraocular IOL lenses, the RxSight Light line. Their technology allows doctors to use ultraviolet light to adjust and optimize the visual acuity of patients.
In 2019, the company began selling its products in the USA. As of March 31, 2021, it delivered 105 devices of its own production, and with the help of RxSight technology, more than 10 thousand operations were performed.
In 2020, the total revenue of RxSight was $14.68 million, which is five times more than in 2019 ($ 2.24 million). And in the first quarter of 2021, the company has already earned $3.5 million.
Earlier, over 6 rounds of financing, RxSight raised more than $186 million. Among the shareholders are large investment funds - Longitude Venture Partners II, RA Capital Healthcare Fund, BP Calhoun Associates and H.I.G. BioVentures - Calhoun, LLC.
According to MarketScope, in 2020, the volume of the addressable market for the IOL lens amounted to $1.4 billion. It is expected to grow at an average annual growth rate of 14% (GAGR) from 2020 to 2026.